Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791934 | 0.92 | MAPT (0.67) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL4879305 | 0.92 | MAPT (0.67) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL14658578 | 0.92 | MAPT (0.67) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL6949058 | 0.85 | MAPT (0.74) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL753207 | 0.85 | MAPT (0.65) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL3540028 | 0.85 | L3MBTL1 (0.70) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL3540036 | 0.85 | L3MBTL1 (0.70) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL670434 | 0.85 | MAPT (0.69) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL594097 | 0.83 | L3MBTL1 (0.69) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL12639913 | 0.83 | L3MBTL1 (0.72) | MAPTALDH1A1LMNAALOX12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-114853846-A | Androgen receptor degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021254464-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-1976938-A | Thienopyrazole derivatives having PDE7 inhibitory activity | ASUBIO PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT1, WNT3, WNT3A | MAPT 734/4885ALDH1A1 1625/4885LMNA 2022/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | MAPT 4520/4885ALDH1A1 968/4885LMNA 2330/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | MAPT 468/4885ALDH1A1 2846/4885LMNA 1044/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | MAPT 4119/4885ALDH1A1 2864/4885LMNA 4644/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | MAPT 569/4885ALDH1A1 1282/4885LMNA 2275/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | MAPT 1496/4885ALDH1A1 1694/4885LMNA 2134/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | MAPT 4520/4885ALDH1A1 968/4885LMNA 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.